ArticleFrontiers in aging neuroscience2025
Clinical analysis of sarcopenia prevalence and its influencing factors in patients with Parkinson's disease.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with Parkinson's disease (PD) have a high risk of sarcopenia. Herein, we evaluated the prevalence of sarcopenia and factors associated with it in ambulatory patients with PD. Methods: Ambulatory patients with PD up to Hoehn and Yahr stage III were included and evaluated based on age, sex, disease duration, levodopa equivalent daily dose, cognitive impairment, swallowing disturbance, history of falling, the Japanese version of the movement disorder society-sponsored revision of the unified PD rating scale (MDS-UPDRS) parts I-IV, quality of life (QoL), and blood test (total protein, albumin, and anemia). Cognitive impairment was assessed using the Japanese version of Mini-Mental State Examination and the Japanese version of the Montreal Cognitive Assessment, whereas swallowing disturbance was assessed using the Japanese version of the Swallowing Disturbance Questionnaire. QoL was assessed using the Parkinson's Disease Questionnaire (PDQ-8). Sarcopenia was diagnosed based on handgrip strength, five-time chair stand test, and skeletal muscle mass. Results: Overall, 97 patients with PD (55 males), with a mean age of 69.8 years and a mean disease duration of 7.3 years, were included. The prevalence of sarcopenia was 33.0%. There were significant differences between the sarcopenia and the non-sarcopenia groups in age, sex, swallowing disturbance, MDS-UPDRS part III total score, and the sub-items arising from a chair, postural stability, and global spontaneity of movement ( Conclusion: In clinical management, it is important to assess muscle strength and evaluate sarcopenia, particularly in patients with PD who have being female, cognitive impairment, or swallowing disturbance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.